Effect of COVID-19 Pandemic on Diagnosis and Treatment Delays in Urological Disease: Single-Institution Experience
Authors Li Z, Jiang Y, Yu Y, Kang Q
Received 8 January 2021
Accepted for publication 17 February 2021
Published 4 March 2021 Volume 2021:14 Pages 895—900
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Marco Carotenuto
Zhen Li,1,* Yu Jiang,2,* Yang Yu,3,* Qianyu Kang3,*
1Department of Urology, The Fifth People’s Hospital of Dalian, Dalian, Liaoning, People’s Republic of China; 2Department of Pediatrics, Dalian Municipal Women and Children’s Medical Center, Dalian, Liaoning, People’s Republic of China; 3Department of Urology, The Second Hospital of Dalian Medical University, Dalian, Liaoning, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Qianyu Kang; Yang Yu
Department of Urology, The Second Hospital of Dalian Medical University, 467 Zhongshan Road, Shahekou District, Dalian, Liaoning, 116023, People’s Republic of China
Email [email protected]; [email protected]
Purpose: In the background of the global pandemic, we aim to investigate the effect of COVID-19 on diagnosis and treatment delay in urology patients.
Patients and Methods: A total of 4919 inpatients were identified from the urological department in our institution, including 2947 and 1972 patients within 9 months before and after the outbreak (group A and group B). The baseline characteristics and residential population of different types of diseases were compared in the two groups. Patients who underwent delay of diagnosis or treatment with poor outcomes were described.
Results: Our result revealed a 33.1% decrease of total resident population as well as a 44.8% decline in bed utilization rate after the outbreak. Significant differences were found between group A and group B in gender (P=0.024) and patients living alone or not (P=0.026). The hospitalization rate of patients with malignancy increased significantly while that of benign patients decreased during the epidemic (P< 0.001). Besides, we identified 5 cases with bladder cancer and 3 cases with prostate cancer that underwent delay of diagnosis or treatment with unfavorable consequences.
Conclusion: With the impact of COVID-19, delay in diagnosis or treatment of non-COVID-19 diseases is inevitable whether the medical resources allocation is effective or not. Psychological status of patients might be the major cause of postponing diagnosis or treatment. For urological patients with locally advanced tumor or rapid progression, who need long-term postoperative intervention, the delay of regular treatment could lead to inevitable progression or recurrence.
Keywords: COVID-19, benign disease, prostate cancer, bladder cancer
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]